Kodiak Sciences Inc. is a biopharmaceutical company focused on developing breakthrough therapeutic treatments for retinal diseases and other serious eye conditions
The company specializes in creating innovative therapies that harness the potential of biologics to address significant unmet medical needs in the field of ophthalmology. Its research is aimed at providing long-term solutions with the goal of improving patients' vision and quality of life, while also reducing the burden on healthcare systems. Through its advanced drug development programs, Kodiak is committed to pioneering new standards of care in eye health.
U.S. stocks traded mixed this morning, with the Dow Jones index trading almost flat on Thursday. Following the market opening Thursday, the Dow traded down 0.02% to 39,753.17 while the NASDAQ fell 0.08% to 16,385.80. The S&P 500 also rose, gaining, 0.04% to 5,250.38.
Shares of Kodiak Sciences Inc. (NASDAQ: KOD) fell sharply during Thursday’s session after the company reported a wider-than-expected fourth-quarter loss. Kodiak Sciences posted a quarterly loss of $1.13 per share, compared to market expectations for a loss of 77 cents per share.
Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.
Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million.
